Bulgarian AI Sales Platform Estel Technologies Secures €270,000 in Pre-Seed Funding

Estel Technologies, a Bulgarian AI‑native sales platform for tech staffing firms, raised €270,000 in a pre‑seed round led by Vitosha Ventures, with participation from angel investor Kerem Basak, to enhance its demand verification and lead‑scoring technology and expand across Europe and into the US.

Slovenian genomics firm GenePlanet attracts strategic investment from Lauxera Capital Partners

Slovenian genomics and laboratory company GenePlanet secured a strategic investment from Lauxera Capital Partners. The deal also saw early investor BlackPeak Capital partially exit while staying on the cap table, providing GenePlanet with additional capital to expand its genetic testing and next‑generation sequencing services across Europe.

Romanian Fertilizer Producer Norofert Secures $15M Investment from US Fund GEM Global Yield

Romanian fertilizer maker Norofert secured a financing agreement with US fund GEM Global Yield that allows the fund to purchase up to $15 million of shares from major shareholder Vlad Popescu over three years, with the proceeds earmarked for scaling production and expanding into the US and Brazilian markets.

Romanian Autonom Services Raises €30 Million Through Bucharest Stock Exchange Bond Listing

On 27 July 2026, Romanian company Autonom Services placed a €30 million autonomous bond (AUT31E) with a 5.97% fixed coupon on the Bucharest Stock Exchange. The issue, consisting of 300 bonds of €100,000 each, was oversubscribed by nine institutional investors and will fund the firm’s growth and sustainability plans.

Polish Startup Heliax Tackles Chronic Pelvic Pain Diagnosis With New Digital Solution

The article describes how Emilia Lewicka, after more than ten years of searching for a diagnosis for chronic pelvic pain, co‑founded the Polish startup Heliax in Wrocław. The company aims to reduce the costly and lengthy diagnostic process—often exceeding 50,000 PLN—by offering the Vitabloom solution, thereby shortening patients’ years of uncertainty.